Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Neoadjuvant Chemotherapy in Stage IIIA(N2) NSCLC (SAKK 16/14)
NCT02572843Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2016
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Event-free Survival Rate at 12 months. Started Jun 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02572843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572843.